-
1.发明专利Heparan sulfate glycosaminoglycan lyase and use thereof 审中-公开HEPARAN SULFATE GLYCOSAMINOGLYCAN LYASE及其用途
公开(公告)号：JP2012213397A
公开(公告)日：2012-11-08
申请号：JP2012125675
申请日：2012-06-01
Applicant: Momenta Pharmaceuticals Inc , モメンタ ファーマシューティカルズ インコーポレイテッド
Inventor： MYETTE JAMES
IPC: C12N15/09 , A61K31/727 , A61K38/51 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P19/02 , A61P27/02 , A61P35/00 , A61P43/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/88 , C12P19/00 , C12Q1/527
CPC classification number: C12N9/1051 , C08B37/0078 , C08B37/0081 , C12P19/26
Abstract: PROBLEM TO BE SOLVED: To provide recombinant B. thetaiotaomicron GAG lyase polypeptides.SOLUTION: The invention provides the recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions are also provided.
Abstract translation: 待解决的问题：提供重组B.泰坦菌素GAG裂解酶多肽。 解决方案：本发明提供了重组大豆多核苷酸GAG裂解酶多肽。 本发明还提供了编码这种多肽的核酸分子，含有二氧化全新世代大豆GAG裂解酶核酸分子的重组表达载体，以及引入了表达载体的宿主细胞。 还提供了利用组合物的表征，诊断和治疗方法。 版权所有（C）2013，JPO＆INPIT
-
公开(公告)号：JP2014205704A
公开(公告)日：2014-10-30
申请号：JP2014132643
申请日：2014-06-27
Applicant: モメンタ ファーマシューティカルズ インコーポレイテッド , Momenta Pharmaceuticals Inc , モメンタ ファーマシューティカルズ インコーポレイテッド
Inventor： MALLIK SUNDARAM , TAKASHI KEI KISHIMOTO , ROY SUCHARITA
IPC: A61K31/7024 , A61K9/08 , A61K9/107 , A61K31/337 , A61K31/7068 , A61K31/727 , A61K45/00 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P43/00
CPC classification number: C08B37/0078 , A61K31/727
Abstract: 【課題】実質的な抗凝固活性を欠くが、他の非凝固媒介生物学的プロセスにおける活性を保持する多糖製剤、並びにそれを製造及び使用する方法の提供。【解決手段】以下の特徴:50%未満のグリコール分割ウロン酸残基を有する;多糖鎖1本当たり3個以下のグリコール分割ウロン酸残基(UG)を有する;40%を超えるU2SHNS,6S二糖残基を有する;製剤の脱硫酸化度が40%未満である;製剤中の1つまたは複数の多糖鎖が、非還元性ウロン酸末端残基の4,5−不飽和を有する;製剤中の1つまたは複数の多糖鎖が、還元性末端に2,5−アンヒドロマンニトール残基を有する;製剤の重量平均分子量が3,500〜7,000ダルトンである;のうちの1つまたは複数を有し得る。【選択図】なし
Abstract translation: 要解决的问题：提供缺乏基本上抗凝活性但在其它非凝固介导的生物过程中保留活性的多糖制剂及其制备和使用方法。溶液：该制剂可以获得以下特征的一个或多个 ：具有少于50％的乙二醇分解的糖醛酸残基; 每个多糖链具有3个或更少的乙二醇分解的糖醛酸残基（UG）; 具有超过40％的U2SHNS，6S二糖残基; 制剂的脱硫氧化程度小于40％; 制剂中一个或多个多糖链具有不含还原糖醛酸末端残基的4,5-不饱和键; 制剂中一个或多个多糖链在还原末端具有2,5-脱水甘露糖醇残基; 制剂的重均分子量为3,500至7,000道尔顿。
-
公开(公告)号：JP2009175143A
公开(公告)日：2009-08-06
申请号：JP2009004460
申请日：2009-01-13
Applicant: Momenta Pharmaceuticals Inc , モメンタ ファーマシューティカルズ インコーポレイテッド
Inventor： VENKATARAMAN GANESH , SASISEKHARAN RAM , SUNDARAM MALIKARJUN , SHRIVER ZACHARY , QI YI-WEI
IPC: G01N27/62 , A61K31/726 , A61K31/727 , A61K45/00 , A61P7/02 , A61P9/06 , A61P9/10 , A61P9/14 , A61P11/00 , A61P11/06 , A61P11/16 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/06 , A61P25/28 , A61P27/02 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/08 , C08B37/00 , C08B37/10 , G01N27/64 , G01N33/53 , G01N33/66 , G01N33/86
CPC classification number: G01N33/66 , G01N33/86 , G01N2400/10 , G01N2400/40 , Y10T436/143333 , Y10T436/17 , Y10T436/24
Abstract: PROBLEM TO BE SOLVED: To provide a method for analyzing and monitoring a group of nonuniform sulfurated polysaccharides. SOLUTION: The method for analyzing a composition sample containing the polysaccharides is provided, by causing a structural feature of the sample to determine one or more primary products selected among: (a) the existence or the quantity of one or more component sugars or disaccharides; (b) the existence or the quantity of one or more block components as components composed of a plurality of sugars or polysaccharides; (c) the existence or the quantity of a representative of one or more sugars modified so as to enhance the detection possibility; (d) the existence or the quantity of parameters regarding an index of a three-dimensional structure or the three-dimensional structure; and (e) the existence or the quantity of one or more modified sugars varied, when a preparation is produced although the modified sugars exist in an initiation material used for producing the preparation. COPYRIGHT: (C)2009,JPO&INPIT
Abstract translation: 要解决的问题：提供一种用于分析和监测一组不均匀硫化多糖的方法。 提供了分析含有多糖的组合物样品的方法，通过使样品的结构特征确定一种或多种选自以下的初级产物：（a）一种或多种组分糖的存在或数量 或二糖; （b）作为由多种糖或多糖组成的组分的一种或多种嵌段组分的存在或数量; （c）修改的一种或多种糖的代表的存在或数量以增强检测可能性; （d）关于三维结构或三维结构的指标的参数的存在或数量; 和（e）当生产制剂时一种或多种改性糖的存在或数量不同，尽管修饰的糖存在于用于制备制剂的起始材料中。 版权所有（C）2009，JPO＆INPIT
-
公开(公告)号：US12297256B2
公开(公告)日：2025-05-13
申请号：US17739912
申请日：2022-05-09
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： Thomas E. Prod'Homme , Leona E. Ling , Carlos J. Bosques , Anthony Manning , Ganesh Kaundinya
Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
-
公开(公告)号：US20240279703A1
公开(公告)日：2024-08-22
申请号：US18218535
申请日：2023-07-05
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： Naveen Bhatnagar , Robin Meccariello , Jonathan C. Lansing , Daniel Ortiz , Hetal Sarvaiya , Nathaniel J. Washburn
CPC classification number: C12P21/005 , C07K16/00 , C12N9/1081 , C12Q1/48 , C12Y204/99001 , C12Y204/99003 , C07K2317/41 , C07K2317/52 , G01N2333/91091 , G01N2440/38
Abstract: Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described.
-
Patent Agency Ranking
公开(公告)号：US20240209040A1
公开(公告)日：2024-06-27
申请号：US18520171
申请日：2023-11-27
Applicant: MOMENTA PHARMACEUTICALS, INC.
Inventor： Carlos J. Bosques , Jonathan C. Lansing , Daniel Ortiz
CPC classification number: C07K14/47 , A61K39/0008 , A61P19/02 , A61P37/06 , A61K2039/577 , C07K2319/30
Abstract: The present disclosure relates to engineered IgG Fc constructs and uses thereof.
-
公开(公告)号：US20240158508A1
公开(公告)日：2024-05-16
申请号：US18351827
申请日：2023-07-13
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： Marilyn Kehry , David J. King , Leona E. Ling , James Meador, III , Sucharita Roy , Anthony Manning
IPC: C07K16/28
CPC classification number: C07K16/283 , A61K2039/505
Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
-
公开(公告)号：US20240067757A1
公开(公告)日：2024-02-29
申请号：US18298131
申请日：2023-04-10
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： Jonathan C. Lansing , Carlos J. Bosques , Daniel Ortiz
IPC: C07K16/46 , A61K39/395 , A61P37/06 , C07K16/00
CPC classification number: C07K16/46 , A61K39/395 , A61P37/06 , C07K16/00 , C07K16/468 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/60 , C07K2317/94 , C07K2319/30
Abstract: The present disclosure relates to compositions and methods of engineered IgG Fc constructs, wherein the Fc constructs include one or more Fc domains.
-
公开(公告)号：US11827682B2
公开(公告)日：2023-11-28
申请号：US17527741
申请日：2021-11-16
Applicant: MOMENTA PHARMACEUTICALS, INC.
Inventor： Carlos J. Bosques , Jonathan C. Lansing , Daniel Ortiz
CPC classification number: C07K14/47 , A61K39/0008 , A61P19/02 , A61P37/06 , A61K2039/577 , C07K2319/30
Abstract: The present disclosure relates to engineered IgG Fc constructs and uses thereof.
-
公开(公告)号：US20230192814A1
公开(公告)日：2023-06-22
申请号：US17925999
申请日：2021-05-19
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： John Schaeck
CPC classification number: C07K16/06 , C12N9/1051 , C12Y204/01038 , C12N9/1048 , C07K2317/41 , C07K2317/55 , C07K2317/52
Abstract: Methods for preparing hypersialylated IgG are described.
-
-
-
-
-
-
-
-
-
Search Results
892
records
(took 0.045 seconds)
